Mutation in RPGRIP1 gene can lead to blindness in children and adults due to a rare eye disease. Odylia Therapeutics is creating a new model for the development of rare disease treatments. They focus on safety, efficacy, and the use of genetic technologies, not on profits. This means they rely on donations to fund gene therapy programs.

The RPGRIP1 Gene Therapy Program is in late stage preclinical testing and recent results from their initial manufacturing process are promising. They are committed to continuing progress but they need your support to achieve their goal of starting clinical trials for RPGRIP1 in 2025.

They are launching the RPGRIP1 Gene Therapy Program Fundraising Campaign to raise $400,000 by September 2023. Reaching this short-term goal will ensure the program doesn't stall and is an important step toward the long-range goal of raising $2 million by the spring of 2024.

It is important to develop a treatment for rare diseases like RPGRIP1 and to get this to patients as quickly, and as safely, as possible. Working together, we can change lives.

As someone, who has family members hopeful to benefit from this treatment, I’d like to raise $1,000 by September 15, 2023. Please consider donating, if you want to support this cause.